Plain-English translation of NCT07629596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called Arnovie101, an mRNA-based therapy that works by helping your body's immune system target and control harmful B cells — the cells that cause lupus and autoimmune hemolytic anemia. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help people whose disease hasn't improved with standard treatments. This is an early-stage study, so the main goal is to gather safety information.
Lupus and autoimmune hemolytic anemia can be very difficult to treat, and some people don't respond well enough to the medicines currently available. This medication represents a new approach that aims to directly quiet the immune cells causing the disease, rather than just managing symptoms.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the medication as an infusion. The study will monitor your safety closely with blood tests and visits to check how your body is responding. Because this is a very early trial with only about 5 participants, the researchers will watch you carefully to make sure the treatment is safe before considering next steps. You'll need to keep taking your current lupus or anemia medications as directed and remain available for follow-up appointments and lab work.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China